Episode
Grey Matters receives first Brain PET scanner for flagship Florida Alzheimer's clinic
- Published
- Jul 6, 2026
- Duration seconds
- 303
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/proactive-interviews-for-investors-1457173/episodes/grey-matters-receives-first-brain-pet-scanner-for-flagship-florida-alzheimer-s-clinic/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/grey-matters-receives-first-brain-pet-scanner-for-flagship-florida-alzheimer-s-clinic.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Grey Matters Health CEO Christopher Moreau joined Steve Darling from Proactive to discuss the arrival of the company’s first brain-dedicated PET scanning system for its flagship NovaScan Neuroimaging Clinics™ location, which is scheduled to open soon in Davie, Florida. Moreau said the clinic will be the first in the United States dedicated exclusively to brain PET imaging, helping address growing demand for the early detection of Alzheimer’s disease through beta-amyloid imaging, while also supporting diagnosis of other neurodegenerative disorders. The facility will feature the U.S. FDA-cleared CareMiBrain™ PET system, an innovative scanner that produces high-quality brain images without requiring an integrated CT scanner. The design reduces patient radiation exposure by approximately 25% while offering a more comfortable chair-style scanning experience. In addition to Alzheimer's disease, the CareMiBrain system will support imaging for Parkinson’s disease, frontotemporal dementia, Lewy body dementia, and selected neuro-oncology applications. Moreau noted that brain PET scans used to detect beta-amyloid plaques are covered by Medicare, Medicaid, and many private insurance plans for eligible patients aged 65 and older. Demand for these scans has also increased following the FDA approval of Leqembi and Kisunla, two monoclonal antibody treatments that slow the progression of Alzheimer's disease. Patients must receive a positive beta-amyloid brain scan—or an approved alternative diagnostic test—to qualify for these therapies, and ongoing imaging is required to monitor treatment response. Management believes the combination of expanded insurance coverage, new Alzheimer's therapies, and growing demand for early diagnosis creates a significant opportunity for NovaScan as it la…